Want to see HK:2576 full AI Analyst Report?
2576 Stock Chart & Stats
HK$4.20
-HK$0.14(-3.49%)
At close: 4:00 PM EST
HK$4.20
-HK$0.14(-3.49%)
Day’s Range― - ―
52-Week RangeHK$3.38 - HK$7.50
Previous CloseN/A
Volume77.00K
Average Volume (3M)61.29K
Market Cap
HK$3.54B
Enterprise ValueHK$2.21B
Total Cash (Recent Filing)HK$1.19B
Total Debt (Recent Filing)HK$61.13M
Price to Earnings (P/E)―
Beta1.22
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding200,592,530
10 Day Avg. Volume68,100
30 Day Avg. Volume61,293
Financial Highlights & Ratios
PEG Ratio0.59
Price to Book (P/B)1.79
Price to Sales (P/S)4.02
P/FCF Ratio-46.47
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Balance Sheet StrengthConsistently low debt-to-equity (~3%–6%) gives the company durable financial flexibility to fund growth initiatives, absorb operating losses, and avoid immediate refinancing pressure. This conservative capital structure reduces solvency risk and supports multi‑quarter execution without forced asset sales.
Improving Gross Margin And Revenue ReboundA large 2025 revenue rebound and gross margin rising to ~42% indicate improving unit economics and stronger core product profitability. Higher gross margins create structural leverage to scale operating profit as fixed costs are absorbed, improving the path to sustainable earnings over several quarters.
Narrowing Losses / Operational ImprovementSignificant narrowing of net losses (to about -8% in 2025) reflects material operational progress versus prior years. Sustained margin improvement reduces cumulative funding needs and demonstrates that management actions are beginning to stabilize results, which supports durability in the turnaround thesis if continued.
Bears Say
Persistent Negative Cash FlowConsistent negative operating and free cash flow across the reported period means the business continues to consume capital rather than generate it. Over multiple quarters this increases financing and dilution risk, constrains reinvestment capacity, and makes long‑term planning dependent on external capital availability.
Still Loss-Making At Operating LevelOngoing negative EBIT/EBITDA shows core operations have not reached recurring profitability. Until operating profits turn positive, the company cannot self-fund growth or demonstrate sustainable return on capital, keeping execution and funding risk elevated over the medium term.
Volatile Cash Flow And FCF DeteriorationA sharp ~62% decline in free cash flow in 2025 highlights volatility in cash generation even amid revenue rebounds. Such swings complicate forecasting, increase the chance of interim funding needs, and can delay or reduce strategic investments, raising structural execution risk over multiple quarters.
Zhejiang Taimei Medical Technology Co Ltd Class H News
2576 FAQ
What was Zhejiang Taimei Medical Technology Co Ltd Class H’s price range in the past 12 months?
Zhejiang Taimei Medical Technology Co Ltd Class H lowest stock price was HK$3.38 and its highest was HK$7.50 in the past 12 months.
What is Zhejiang Taimei Medical Technology Co Ltd Class H’s market cap?
Zhejiang Taimei Medical Technology Co Ltd Class H’s market cap is HK$3.54B.
When is Zhejiang Taimei Medical Technology Co Ltd Class H’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Zhejiang Taimei Medical Technology Co Ltd Class H’s earnings last quarter?
Currently, no data Available
Is Zhejiang Taimei Medical Technology Co Ltd Class H overvalued?
According to Wall Street analysts Zhejiang Taimei Medical Technology Co Ltd Class H’s price is currently Overvalued.
Does Zhejiang Taimei Medical Technology Co Ltd Class H pay dividends?
Zhejiang Taimei Medical Technology Co Ltd Class H does not currently pay dividends.
What is Zhejiang Taimei Medical Technology Co Ltd Class H’s EPS estimate?
Zhejiang Taimei Medical Technology Co Ltd Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Zhejiang Taimei Medical Technology Co Ltd Class H have?
Zhejiang Taimei Medical Technology Co Ltd Class H has 200,592,530 shares outstanding.
What happened to Zhejiang Taimei Medical Technology Co Ltd Class H’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Zhejiang Taimei Medical Technology Co Ltd Class H?
Currently, no hedge funds are holding shares in HK:2576
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Zhejiang Taimei Medical Technology Co Ltd Class H Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Company Description
Zhejiang Taimei Medical Technology Co Ltd Class H
Zhejiang Taimei Medical Technology Co., Ltd., established in 2013 and based in Jiaxing, China, specializes in delivering sophisticated digital operational platforms specifically designed for the biopharmaceutical industry across the country. The company's core offering is TrialOS, a comprehensive digital collaboration platform that seamlessly integrates all participants throughout the drug development and research lifecycle. This ecosystem effectively links hospitals, pharmaceutical firms, external service providers, regulatory bodies, and patients, among other key industry stakeholders. Its extensive portfolio of software solutions caters to various critical aspects of clinical research and drug development. For streamlining clinical trial operations, Taimei Medical provides tools like eCooperate, which optimizes management systems and leverages big data for informed decision-making. Other related offerings include eArchives for managing master files, eCollect for electronic data capture, eCollege for training administration, eQuality for electronic audit processes, and eBalance for interactive web-based responses. Innovations such as eVisit Patient Reported Outcomes are designed to enhance patient data input and accuracy, while eTime supports project time management, and eImage facilitates medical image interpretation. Furthermore, the company supplies specialized software tailored for hospitals and Good Clinical Practice (GCP) sites. These include eTrial for managing Phase I wards, eSite and NomenCTMS for comprehensive clinical trial management at study sites, and intelligent platforms like GCP-X and Intelligent Investigator. Solutions such as eScreening assist with subject information management and deduplication, while IIT-EDC and the Investigator-Initiated Clinical Trial Management System support investigator-initiated studies and their associated data management. In the crucial domain of drug safety, the company offers robust pharmacovigilance software solutions. This includes both global and intelligent eSafety systems, alongside the SAE Manager for efficient communication and management of critical safety data during clinical trials. Complementing these, Zhejiang Taimei also develops marketing software and a variety of other digital innovation solutions.
Zhejiang Taimei Medical Technology Co Ltd Class H (2576) Earnings & Revenues
Technical Analysis
Century Sage Scientific Holdings Ltd
―
Aurum Pacific (China) Group Ltd.
―
Sinopharm Tech Holdings Limited
―